D‐512, a novel dopamine D(2/3) receptor agonist, demonstrates greater anti‐Parkinsonian efficacy than ropinirole in Parkinsonian rats

BACKGROUND AND PURPOSE: Symptoms of Parkinson's disease are commonly managed using selective dopamine D(2/3) receptor agonists, including ropinirole. While D(2/3) agonists are useful in early‐stage Parkinson's disease, they tend to lose efficacy in later disease stages and do not appear to...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Pharmacol
Main Authors: Lindenbach, David, Das, Banibrata, Conti, Melissa M, Meadows, Samantha M, Dutta, Aloke K, Bishop, Christopher
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Research Papers
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573415/
https://ncbi.nlm.nih.gov/pubmed/28667675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13937
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki